Japan, United Kingdom and Italy Formally Announce Joint Development of a Next-Generation Fighter JCN Newswire

Japan, United Kingdom and Italy Formally Announce Joint Development of a Next-Generation Fighter

December 9, 2022
TOKYO, Dec 9, 2022 - (JCN Newswire via SEAPRWire.com) - The Government of Japan today announced the joint development of the country's next-generation fighter together with partners in the U.K. and Italy.In recent years, Mitsubishi Heavy Industries, Ltd. (MHI) has developed cutting-edge technologies for fighter through diverse research initiatives, including the "X-2," an advanced technology demonstrator jet. Since October 2020, when a contract was concluded with the Ministry of Defense on development of the future fighter aircraft (F-X), MHI has conducted a conceptual design and other development-related work. Simultaneously, MHI has been looking into the feasibility of collaboration with the U.K. and Italian defense industries under the leadership of the governments of the three nations.Following the formal announcement of the joint development by the three nations' governments, the development program will now go forward concurrently in Japan, the U.K. and Italy. MHI will work closely with the government authorities and corporate partners from all three nations, in order to develop the next-generation fighter, pooling our respective cutting-edge technologies and expertise.This international collaborative project, with the broad participation of Japan's defense companies, will foster innovation in the country's industrial sector such as digital transformation, as well as the development of human resources in the field of science and technology. Through its development of the next-generation fighter, MHI will strengthen the country's defense industrial base as a whole and continue making significant contributions to Japan's national security.About MHI GroupMitsubishi Heavy Industries (MHI) Group is one of the world's leading industrial groups, spanning energy, smart infrastructure, industrial machinery, aerospace and defense. MHI Group combines cutting-edge technology with deep experience to deliver innovative, integrated solutions that help to realize a carbon neutral world, improve the quality of life and ensure a safer world. For more information, please visit www.mhi.com or follow our insights and stories on spectra.mhi.com. Copyright 2022 JCN Newswire. All rights reserved. (via SEAPRWire)
More

AIM Vaccine, a Major Player in the Chinese Vaccine Industry Successfully Listed on the Main Board of SEHK

October 6, 2022
HONG KONG, Oct 6, 2022 - (ACN Newswire via SEAPRWire.com) - AIM Vaccine Co., Ltd. ("AIM Vaccine" or the "Company", together with its subsidiaries, the "Group", stock code: 06660.HK), the second largest vaccine company in China in terms of 2021 approved lot release volume (excluding COVID-19 vaccines), was successfully listed and commenced trading on the Main Board of The Stock Exchange of Hong Kong Limited ("SEHK") today, with a board lot of 200 H shares each. The debut of AIM Vaccine's stock price was very outstanding on 6 October. The share price closed at HK$16.66, up 3.09%.Goldman Sachs (Asia) L.L.C., China International Capital Corporation Hong Kong Securities Limited, China Securities (International) Corporate Finance Company Limited and Macquarie Capital Limited are the Joint Sponsors, Joint Global Coordinators, Joint Bookrunners and Joint Lead Managers. BOCI Asia Limited, CMB International Capital Limited, Futu Securities International (Hong Kong) Limited, and Tiger Brokers (HK) Global Limited are the Joint Bookrunners and Joint Lead Managers. ICBC International Capital Limited is Joint Bookrunner, ICBC International Securities Limited and Livermore Holdings Limited are the Joint Lead Managers.The Company said that the listing of AIM Vaccine in Hong Kong marks a key milestone and unfolds a new chapter in the Company's development. Looking ahead, AIM Vaccine will continue to strive to access to quality industry resources to expand and optimize its business. The Company will keep abreast of the most advanced platform technologies and innovation trends, accelerating the development of vaccine candidates and continuing to enrich its product portfolio, solidifying and expanding market leadership by increasing sales and marketing efforts for approved vaccine products and commercializing new products, thereby realizing its mission to "develop and manufacture top quality vaccines to safeguard the health of the world", becoming a world-class vaccine company in the global vaccine market and creating greater value for shareholders. Copyright 2022 ACN Newswire. All rights reserved. (via SEAPRWire)
More